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Abstract
Background: Our previous genome-wide gene expression analysis revealed that tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL) death receptors 4 (DR4) and 5 (DR5) are markedly upregulated by the ethanolic
extract of D. sohia seeds (EEDS) in A549 TRAIL-refractory cancer cells. In the present study, we investigated whether
the EEDS-mediated upregulation of TRAIL death receptors was associated with increased TRAIL-mediated toxicity in
A549 cells in vitro.
Methods: Cell proliferation and viability were determined by an automatic cell counter. Gene silencing was performed
by introducing small interfering RNA into cells. Expression changes of cellular proteins were determined by western
blot analysis. Apoptotic cell death was monitored by western blot analysis. Analysis of variance followed by the
post-hoc Dunnett’s test was used to compare the data.
Results: EEDS treatment increased both mRNA and protein levels of DR4 and DR5 in the TRAIL refractory A549
cells. Co-treatment of A549 cells with sub-lethal dose of EEDS and recombinant TRAIL increased the apoptotic
cell death. Upregulation of DR5 by EEDS was mediated by an endoplasmic reticulum stress-induced transcription
factor, CCAAT/enhancer-binding protein homologous protein (CHOP), and knockdown of CHOP expression inhibited
EEDS-induced DR5 upregulation and abolished the EEDS-associated increase in TRAIL toxicity in A549 cells.
Conclusions: EEDS can sensitize A549 cells to TRAIL cytotoxicity by upregulation of TRAIL death receptors. Our findings
suggested that EEDS is a good initial herbal source for the development of an anticancer supplement for anticancer
therapeutics associated with TRAIL.
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Background
Cancer is the leading cause of death, and the prevalence
of cancer continues to rise despite advances in earlier
diagnosis, clinical intervention, and increased public
awareness of the risk factors for cancer [1]. The muta-
tion of regulatory genes that are involved in maintaining
the equilibrium between cell proliferation and cell death
creates cancer cells that undergo rapid, uncontrolled cell
division and evade cell death [2]. Current standard cancer
therapies involve surgery to remove the major tumor
masses and subsequent radiotherapy and/or chemother-
apy to kill potential remaining cancer cells and to prevent
cancer recurrence. A drawback of these conventional
radio-chemotherapies is their lack of specificity: they can-
not discriminate cancer cells from normal cells, resulting
in the substantial death of normal cells, which causes ad-
verse side effects, such as gastro-intestinal complications,
appetite loss, bone marrow/hematological complications,
fatigue, weight loss, and pain [3]. The side effects may affect
the quality of life of cancer patients, and moreover, they
complicate the therapies and thereby affect the prognosis
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and survival of cancer patients [3]. Therefore, the ideal anti-
cancer therapeutics should exclusively target cancer cells
while sparing normal cells [4].
In the mid-1990s, tumor necrosis factor (TNF)-related
apoptosis-inducing ligand (TRAIL), a new member of
the TNF superfamily, was discovered [5, 6]. As a cytotoxic
cytokine, TRAIL selectively induces apoptosis in tumor
cells through homotrimeric binding to the membrane-
bound death receptor 4 (DR4, also known as TRAIL-
receptor 1 or TNF receptor superfamily member 10A) and
death receptor 5 (DR5, also known as TRAIL-receptor 2 or
TNF receptor superfamily member 10B), the recruitment
of Fas-associated death domain protein (FADD), the
formation of the death-inducing signaling complex
(DISC), and the subsequent activation of caspase-8 and
effector caspase-3 (extrinsic pathway). Activated caspase-8
also triggers the intrinsic apoptotic pathway by cleaving
BH3-interacting domain death agonist (Bid); truncated
Bid translocates to the mitochondria and induces cyto-
chrome C release from the mitochondria, thereby acti-
vating caspase-9 and caspase-3 [7–9]. TRAIL is an
attractive anticancer therapeutic due to its ability to
induce apoptosis in a broad spectrum of cancer cells
while sparing most normal cells [10–12]. However, the
clinical application of TRAIL therapy has been limited
by its inherently short half-life in blood (3–5 min in
rodents and 24–31 min in non-human primates), in-
sufficient delivery to the targets, and the appearance
of cancer cell populations with intrinsic or acquired
resistance to TRAIL-mediated programmed cell death
[13, 14]. Improvements in the plasma half-life of TRAIL
and delivery efficiency of TRAIL have been attempted by
manipulating its structure, such as by creating fusions
with the immunoglobulin Fc domain [15] or by coupling
or encapsulating TRAIL into liposomes [14, 16]. The de-
velopment of an agonistic monoclonal antibody (mAb) or
chimeric antigen receptors specific for TRAIL receptors
are additional potential strategies for overcoming TRAIL
instability [17].
The issue of cancer cells acquiring TRAIL resistance
can be overcome by the co- or pre-administration of agents
that sensitize refractory cancer cells to TRAIL cytotoxicity.
They include a heat shock protein 90 inhibitor NVP-
AUY922 that suppresses JAK2-STAT3-Mcl-1 signaling
pathway [8], a pan-histone deacetylase inhibitor trichostatin
A isolated from Streptomyces hygroscopius that downregu-
lates cellular FADD-like interleukin-1β-converting enzyme
inhibitory protein (c-FLIP) [13], a phytochemical triptolide
(PG490) isolated from Tripterygium wilfordii that activates
mitogen-activated protein kinase ERK2 [18], a phytochem-
ical carnosic acid isolated from Rosmarinus officinalis that
upregulates death receptor DR5 [19], and a mitochondrial
respiration inhibitor rotenone that reciprocally regulates
DR5 (up-) and c-FLIP (down-) [20]. Certain previous
reports have demonstrated that crude extracts or puri-
fied active phytochemicals from medicinal herbs with
pharmacological activity exert synergistic cytotoxicity
against cancer cells when co-administered with recombin-
ant TRAIL [9, 21–23]. From our previous gene expression
profiling of TRAIL-refractory A549 human lung cancer
cells, we found that DR4 and DR5 expression was enhanced
by treatment with the ethanolic extract of Descurainia
sophia seeds (EEDS) [24]. In this study, we determined
whether the EEDS-mediated upregulation of DR4 and DR5
translated to sensitization of A549 cells to TRAIL cytotox-
icity. Our data suggested that CCAAT/enhancer-binding
protein homologous protein (CHOP), an endoplasmic
reticulum (ER) stress-induced transcription factor, was a
critical regulator of the EEDS-mediated upregulation of
TRAIL death receptors.
Methods
Plant materials and EEDS preparation
The dried seeds of D. sophia were obtained from
Kwangmyungdang Medicinal Herbs Co. (Ulsan, Republic
of Korea) and identified by Dr. Go Ya Choi, K-Herb
Research Center, Korea Institute of Oriental Medicine,
Daejeon, Republic of Korea. A voucher specimen
(KIOM-CRC-5) was deposited at KM-Convergence Re-
search Division, Korea Institute of Oriental Medicine.
EEDS was prepared as described in our previous report
[24]. In brief, the dried seeds of D. sophia (9 kg) were
ground in an electric grinder and were subjected to solv-
ent extraction with 80 % (v/v) of ethanol (40 L). The ex-
traction was performed three times at room temperature.
The extracts were filtered through a Whatman filter paper
(No. 2, Whatman International, Maidstone, England) and
were concentrated using a rotary evaporator (EYELA,
Tokyo Rikakikai, Tokyo, Japan) at 40 °C. The sticky solid
lower extract (535.7 g) was collected and further dried in a
WiseVen vacuum oven (WOW-70, Daihan Scientific,
Seoul, Republic of Korea) at 40 °C for 24 h. The vacuum-
dried powder of EEDS was homogenized using a mortar,
dissolved in 100 % dimethyl sulfoxide (DMSO, Sigma-
Aldrich, St. Louis, MO, USA) to final concentration of
20 mg/mL, and sterilized by passage through 0.22 μm syr-
inge filters (Millipore, Billerica, MA, USA). The sterilized
EEDS stock solution was aliquoted in small volumes and
stored at -80 °C.
Cell culture and reagents
The A549 and NCI-H460 human non-small cell lung
carcinoma (NSCLC) cell lines were directly obtained
from American Type Culture Collection (Rockville, VA,
USA). Lung cancer is the leading cause of cancer deaths
in the Republic of Korea (http://kostat.go.kr) and we have
tried to discover novel anticancer agents targeting lung
cancer, especially NSCLC. We chose A549 and NCI-H460
Park et al. BMC Complementary and Alternative Medicine  (2016) 16:115 Page 2 of 8
cell lines in the present study because they were previously
known as TRAIL-refractory (A549) and sensitive (NCI-
H460) NSCLC cells [25, 26]. Authentication of the cell
lines was done using a short tandem repeat analysis by
Korean Cell Line Bank (Seoul National University College
of Medicine, Seoul, Republic of Korea). These cell lines
were cultured in RPMI1640 basal medium supplemented
with 10 % (v/v) fetal bovine serum, 100 U/mL penicillin,
and 100 mg/mL streptomycin. The cells were grown at
37 °C in a humidified incubator containing 5 % CO2. Cell
growth and viability were determined using an ADAM-
MC automatic cell counter (NanoEnTek, Seoul, Republic
of Korea) as previously described [27]. All the supple-
ments and the basal media for cell culture as well as
recombinant TRAIL were obtained from Invitrogen
(Carlsbad, CA, USA). TRAIL was dissolved in sterile
phosphate-buffered saline (PBS) containing 0.1 % (w/v)
bovine serum albumin (BSA) as a carrier protein.
Western blot analysis
Total protein was prepared using RIPA cell lysis buffer
(Thermo Scientific, Rockford, IL, USA) containing 100 μM
phenylmethylsulfonyl fluoride (Sigma-Aldrich) and an
ethylenediaminetetraacetic acid-free protease inhibitor
cocktail (Roche, Mannheim, Germany). The protein
concentration was determined by the bicinchoninic acid
assay kit (Thermo Scientific). Proteins were separated by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis
and blotted to nitrocellulose membranes (Millipore). The
membranes were blocked with 5 % (w/v) skim milk in
0.1 % (v/v) Tween 20-PBS for 1 h. The blots were probed
with primary antibodies against specific proteins at 4 °C
overnight, and the primary antibodies were then captured
with secondary antibodies conjugated to horseradish per-
oxidase (HRP) for 1 h. The immunoreactive bands were
visualized with ECL (GE Healthcare, Piscataway, NJ,
USA). Rabbit polyclonal anti-DR5 (#3696), -poly ADP
ribose polymerase (PARP) (#9542), -caspase-9 (#9502),
mouse monoclonal anti-caspase-8 (#9746, clone 1C12),
-CHOP (#2895, clone L63F7), and rabbit monoclonal anti-
caspase-3 (#9665, clone 8G10) were obtained from Cell
Signaling Technology (Danvers, MA, USA). Rabbit poly-
clonal anti-DR4 (Ab8414) and mouse monoclonal anti-β-
actin (A1978, clone Ac-15) antibodies were obtained from
Abcam and Sigma-Aldrich, respectively.
Gene silencing of CHOP
A549 cells were plated in a six-well culture plate (105 cells/
well) and incubated for 24 h. The cells were transiently
transfected with CHOP-specific small interfering RNA
(siRNA; sc-35437, Santa Cruz Biotechnology, CA, USA) or
control siRNA (sc-37007, Santa Cruz Biotechnology) using
Lipofectamine 2000 (Invitrogen) according to the user’s
guide. After 48 h, the medium was replaced with fresh
medium containing 5 μg/mL EEDS. The cells were further
incubated for 24 h, and total protein extracts were prepared
for western blot analysis to determine the efficiency of the
CHOP siRNA.
Statistical analysis
The results are expressed as the mean ± standard devi-
ation (SD) of triplicate experiments. Differences in the
continuous variables were analyzed by analysis of vari-
ance followed by the post-hoc Dunnett’s test. Values of
P < 0.05 were considered significant.
Results
TRAIL cytotoxicity was cell type-dependent
First, we tested the cytotoxicity of recombinant TRAIL
in 2 different human NSCLC cell lines, A549 and NCI-
H460. The cells were exposed to increasing concentra-
tions of recombinant TRAIL (0-100 ng/mL) for 48 h,
and cell viability was determined based on membrane
integrity as previously described. Figure 1 shows that
NCI-H460 cells were sensitive to TRAIL: their viability
decreased in a dose-dependent manner. Markedly de-
creased cell viability was observed at ≥50 ng/mL TRAIL,
and more than 30 % of the cell population was dead
after 48 h of TRAIL treatment. However, A549 cells
were resistant to TRAIL cytotoxicity: they maintained
greater than 90 % viability even at 100 ng/mL TRAIL.
This differential TRAIL cytotoxicity between the A549
and NCI-H460 human lung cancer cell lines was consist-
ent with previous reports [25, 26].
TRAIL (ng/mL)




















Fig. 1 Differential sensitivities of lung cancer cells to TRAIL cytotoxicity.
NCI-H460 (black bars) and A549 (gray bars) cells were exposed to
increasing concentrations of TRAIL (0-20 μg/mL) for 48 h, and their
viability was determined based on membrane integrity. The cell
viability is presented relative to vehicle treatment (PBS containing
0.1 % BSA). The data are presented as the mean ± SD of triplicate
experiments. *P <0.05, **P <0.01, ***P <0.01 vs. vehicle control
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EEDS upregulated TRAIL receptors in A549 lung cancer
cells
We previously determined the dose-dependent effects of
EEDS on global gene expression in A549 cells using
microarray analysis [24]. From this gene expression ana-
lysis, we identified two human TRAIL receptors, DR4
and DR5, that were upregulated in a dose-dependent
manner by EEDS. The increased DR4 and DR5 expression
was observed at the low concentration of 1.25 μg/mL
EEDS, and DR4 and DR5 expression increased nearly 7-
fold in response to 20 μg/mL EEDS after 24 h treatment
when compared to vehicle treatment (0.1 % DMSO;
Fig. 2a). To confirm the EEDS-mediated upregulation of
DR4 and DR5, we utilized western blot analysis to de-
termine the intracellular change in DR4 and DR5 pro-
tein expression in response to EEDS. As shown in
Fig. 2b, DR4 and DR5 protein expression increased in a
dose-dependent manner in response to EEDS, and the
intracellular protein levels of DR4 and DR5 began to
increase at 1 μg/mL EEDS.
EEDS sensitized A549 lung cancer cells to TRAIL
After observing the increased expression of the TRAIL
death receptors, DR4 and DR5, in response to EEDS, we
determined whether EEDS increased TRAIL toxicity in
A549 lung cancer cells. A549 cells treated with EEDS
(5 μg/mL) or TRAIL (100 ng/mL) alone maintained
greater than 90 % viability after 24 h. However, cell via-
bility decreased significantly 70 % when A549 cells were
co-treated with EEDS and TRAIL (Fig. 3a). We next de-
termined whether apoptotic cell death was enhanced by
co-treatment with EEDS and TRAIL. A549 cells were
treated with a combination of EEDS (5 μg/mL) and
TRAIL (100 ng/mL) for 24 h, and the protein expression
of apoptosis-related intracellular proteins was determined
by western blotting. As shown in Fig. 3b, the expression of
DR4 and DR5 by was induced in A549 cells by EEDS as
expected. Treatment of cells with EEDS or TRAIL alone
for 24 h did not induce the cleavage of PARP protein in
TRAIL-treated cells. In contrast, co-treatment of cells with
EEDS and TRAIL led to a marked induction of apoptotic
cell death and activation of caspase-3/8/9, which were
revealed by cleavage of intact PARP and procaspases,
respectively. Taken together, these results indicated that
EEDS sensitized A549 lung cancer cells to TRAIL-induced
apoptotic cell death by upregulating TRAIL receptors.
Upregulation of TRAIL receptors by EEDS was mediated
by CHOP
Certain previous studies have revealed that the drug-
induced sensitization of cancer cells to TRAIL occurs
through the upregulation of TRAIL receptors, especially
DR5, which is mediated by the ER stress-induced tran-
scription factor CHOP [19, 28, 29]. Therefore, we inves-
tigated whether EEDS affected CHOP expression in
A549 cells. A549 cells were treated with a combination
of EEDS (5 μg/mL) and TRAIL (100 ng/mL) for 48 h,
and changes in CHOP and DR5 protein expression were
determined by western blot analysis. CHOP protein ex-
pression increased in response to EEDS (Fig. 4a). How-
ever, TRAIL did not affect CHOP expression alone or in
a combination with EEDS. A dose-dependent increase in
intracellular CHOP mRNA expression was observed in
our previous gene chip analysis of EEDS-treated A549
cells [24]. Next, we utilized CHOP siRNA to determine
whether CHOP knockdown inhibited EEDS-induced
DR5 upregulation. Commercially available siRNA against
EEDS (μg/mL)































Fig. 2 EEDS-mediated upregulation of TRAIL receptors. a A549 cells
were treated with various concentrations of EEDS. After 24 h, total
RNA was prepared from the cells, and changes in relative gene
expression in response to EEDS were determined by expression chip
analysis as described in our previous report [24]. The relative
expression of two human TRAIL receptors (DR4, black bars; DR5, grey
bars) in the treatment group is presented compared to vehicle
treatment (PBS containing 0.1 % DMSO). b A549 cells were exposed
to increasing concentrations of EEDS (0-5 μg/mL). After 24 h, DR4
and DR5 protein expression was determined by western blot
analysis. β-actin was included as a loading control
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CHOP successfully decreased intracellular CHOP protein
expression (Fig. 4b). DR5 expression was also downregu-
lated by CHOP siRNA, demonstrating that CHOP is a key
mediator of EEDS-induced DR5 upregulation. The engage-
ment of CHOP in EEDS-induced DR5 upregulation and
apoptotic cell death was further confirmed by the recovery
of cell viability from the synergistic cytotoxicity of EEDS
and TRAIL by pre-treatment of CHOP siRNA (Fig. 4c).
Figure 4d summarizes our findings that EEDS treatment in-
creased the expression of transcription factor CHOP, which
in turn induced the expression of TRAIL death receptors,
such as DR5; more recombinant TRAIL molecules bound
to the increased number TRAIL receptors, ultimately en-
hancing apoptotic cell death.
Discussion
TRAIL is as a promising anticancer therapy that lacks
serious side effects due to its ability to selectively kill
cancer cells without harming most normal cells. How-
ever, some highly malignant tumors are resistant to
TRAIL-induced programmed cell death [30]. The mech-
anisms underlying TRAIL resistance include decreased
expression or dysfunction of DR4 and DR5, defects in the
DISC that comprises FADD and caspase-8, overexpression
of Bcl-2, Bcl-XL, FADD-like interleukin-1β-converting en-
zyme-inhibitory protein or inhibitor of apoptosis protein,
dysfunction of Bax and Bak, decreased release of second
mitochondria-derived activator of caspases (Smac/Diablo)
into the cytosol, and constitutive activation of survival sig-
naling molecules, such as mitogen-activated protein kinase,
Akt, and nuclear factor-kappa-B [20, 30]. Therefore, we hy-
pothesized that TRAIL resistance in cancer cells can be
overcome by reversing the mechanisms by which TRAIL
resistance is established, such as by upregulating DR4 and
DR5, overexpressing pro-apoptotic proteins, downregulat-
ing anti-apoptotic proteins, and inhibiting key factors that
regulate cell survival.
As a complex disease, cancer etiology involves mul-
tiple risk factors; therefore, the treatment of cancer may
require a multi-target approach. Complementary and al-
ternative medicine, which has traditionally used crude
extracts or fractions of medicinal herbs, may offer new
opportunities for cancer treatments involving a multi-
component and multi-target strategy [3]. In this study,
we were the first to demonstrate that the crude extract
of D. sophia seeds effectively sensitized TRAIL-refractory
A549 lung cancer cells to TRAIL-induced apoptosis by
upregulating DR5 at the transcriptional level (Figs. 2 and
3). D. sophia (L.) Webb ex Prantl (Flixweed) is an annual
weed that belongs to the Brassicaceae (Cruciferae) family.
It is widely distributed throughout Europe and temperate
to tropical Asian countries and produces large numbers of
tiny red to brown seeds (0.7–1.5 mm long) from early to
late summer [31]. In traditional folk medicine, different
parts of D. sophia have been used to treat jaundice, feb-
rifuge, laxative, and furuncle in Middle Asia [32] and
for cough, edema, asthma, heart disease, and cancer in
China [33, 34]. A variety of phytochemicals have been
identified from the extracts of aerial parts and seeds of
D. sophia. They are small molecules (amino acids, alcohols,
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Fig. 3 EEDS enhanced TRAIL toxicity in A549 lung cancer cells.
a TRAIL-refractory A549 cells were treated with a combination of
EEDS (E, 5 μg/mL) and TRAIL (T, 100 ng/mL) for 24 h. Cell viability was
determined based on membrane integrity as previously described.
The data are presented as the mean ± SD of triplicate experiments.
***P <0.001. b Enhanced apoptotic cell death in A549 cells by
co-treatment of EEDS (E, 5 μg/mL) and TRAIL (T, 100 ng/mL) for
24 h. Whole cell lysates were prepared and subjected to western
blot analysis using specific antibodies. The arrow indicates the
cleaved forms of PARP. Asterisk indicates the specifically bound
proteins of procaspase-3. β-actin was included as a loading control
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aldehydes, ketones), cardiac glycosides (erysimoside,
evobioside, helveticoside, strophanthidin), coumarins
(bergapten, isoscopoletin, psoralene, scopoletin, xantho-
toxin, xanthotoxol), fatty acids (arachic acid, capric acid,
eicosenoic acid, erucic acid, lauric acid, linoleic acid, lino-
lenic acid, myristic acid, oleic acid, palmitic acid, stearic
acid), flavonoids (drabanemoroside, isoquercitrin, isorham-
netin, isorhamnetin–3-O-β-D-glucopyranoside, kaempferol,
quercetin, quercetin 3-O-α-L-rhamnopyranosyl-(1→ 2)-α-
L-arabinopyranose, quercetin-3-O-β-D-glucopyranoside),
flavonol glycoside (artabotryside A), glucosinolates (gluco-
napin, sinigrin), lactones (descurainolide A and B), lignan
(syringaresinol), nor-lignan (descuraic acid), lipids (epoxya-
cylglyceride, triacylglyceride), phenolic compounds (3,4,5-
tritrimethoxy cinnamic acid, isovanillic acid, p-benzoic
acid, p-hydroxybenzaldehyde, sinapic acid, syringic acid),
phytosterol (daucosterol), sinapoyl glycosides (1,2-di-
O-sinapoyl-β-D-glucopyranose, 1,2-disinapoylgentiobiose,
1,3-di-O-sinapoyl- β-D-glucopyranose), and a unique
group of compounds (descurainin, descurainin A, descurai-
noside, descurainoside A and B) [34–40]. The biological ac-
tivities of the extract of D. sophia, such as analgesic,
antipyretic, anti-inflammatory, and cytotoxic effects may be
attributed to some of aforementioned phytochemicals or
unknown ones, and/or their combination. In the present
study, however, we did not identify the active component(s)
of EEDS responsible for the synergistic anticancer effect
with TRAIL; this discovery remains for future study. The
active components of EEDS can be identified using conven-
tional activity-guided fractionation of crude extracts and
spectroscopic analyses of isolated single phytochemicals.
We also demonstrated that the EEDS-induced upregu-
lation of DR5 was mediated by CHOP, as revealed by the
efficient inhibition of EEDS-induced DR5 expression by
CHOP siRNA. CHOP is a transcription factor that is in-
duced by various stresses, including ER stress (the un-
folded protein response) [29] and reactive oxygen species
(ROS) [41]. Since the relationship between CHOP and
DR5 was discovered in 2004 [42], numerous studies have
shown that the induction of CHOP by stressful stimuli
mediates DR5 upregulation during TRAIL sensitization
via a consensus CHOP-binding element (GAGGATTGC
GATC) in the DR5 promoter [42, 43]. Biologically active
phytochemicals isolated from medicinal plants or their
crude extracts have been reported to enhance TRAIL-
induced apoptosis via CHOP-dependent DR5 upregulation
in cancer cells [21, 29]. In addition to the CHOP-
dependent pathway, CHOP-independent DR5 upregulation
has been observed in certain cancer cells treated with
TRAIL and other chemicals, such as Orlistat (XenicalTM)
[44] and curcumin [45], although the key mediators of DR5
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Fig. 4 CHOP mediated the DR5 upregulation by EEDS. a A549 cells were treated with a combination of EEDS (E, 5 μg/mL) and TRAIL (T, 100 ng/mL)
for 24 h, and the intracellular expression levels of DR5 and CHOP were determined by western blot analysis. b A549 cells were transiently transfected
with control or CHOP siRNA. After 48 h, the cells were treated with 5 μg/mL EEDS for 24 h. Whole cell lysates were prepared, and the intracellular
expression levels of DR5 and CHOP were determined by western blot analysis. β-actin was included as a loading control. c CHOP knockdown
inhibited EEDS-enhanced TRAIL toxicity. A549 cells were transfected with control or CHOP siRNA for 48 h and then treated with a combination
of EEDS (5 μg/mL) and TRAIL (100 ng/mL). Cell viability was determined after 24 h of drug treatment as previously described. The data are
presented as the mean ± SD of triplicate experiments. *P <0.05. d Schematic of the EEDS-mediated sensitization of A549 lung cancer cells
to TRAIL
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Conclusions
In summary, our findings suggested a future model of
integrative anticancer therapy that incorporates a more
stable recombinant TRAIL or agonistic ligand targeting
TRAIL receptors with traditional herbal medicine to
sensitize refractory tumors to TRAIL toxicity. In this as-
pect, EEDS is a suitable initial material for the develop-
ment of an herbal supplement for anticancer therapy.
Further studies should be performed to validate the antitu-
mor efficacy of the combination therapy of TRAIL and
EEDS using a suitable in vivo animal model and to identify
the active component of EEDS that is responsible for the
TRAIL synergism.
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